Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study

References

• Ferri CP, Prince M, Brayne C. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-71Ferri CP, Prince M, Brayne C. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-7
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T. Vascular dementia: challenge of clinical diagnosis. Int Psychogeriatr 1997;9(Suppl 1):51-58; discussion 77-832Erkinjuntti T. Vascular dementia: challenge of clinical diagnosis. Int Psychogeriatr 1997;9(Suppl 1):51-58; discussion 77-83
   PubMedGoogle Scholar
• Konno S, Meyer JS, Terayama Y. et al. Classification, diagnosis and treatment of vascular dementia. Drugs Aging 1997;11:361-733Konno S, Meyer JS, Terayama Y. et al. Classification, diagnosis and treatment of vascular dementia. Drugs Aging 1997;11:361-73
   PubMed Web of Science ®Google Scholar
• Heyman A, Fillenbaum GG, Welsh-Bohmer KA. et al. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to Establish a Registry for Alzheimer's disease. Neurology 1998;51:159-624Heyman A, Fillenbaum GG, Welsh-Bohmer KA. et al. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to Establish a Registry for Alzheimer's disease. Neurology 1998;51:159-62
   Google Scholar
• Lewis H, Beher D, Cookson N. et al. Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol 2006;32:103-185Lewis H, Beher D, Cookson N. et al. Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol 2006;32:103-18
   PubMed Web of Science ®Google Scholar
• A strategic report highlighting research priorities that will tackle the prevention and treatment of vascular dementia. The Alzheimer's Society, UK. Available from http://www.alzheimers. org.uk/downloads/report_to_summarise_research_priorities_to_ tackle_vascular_dementia.pdf[Accessed 14/3/2008]6A strategic report highlighting research priorities that will tackle the prevention and treatment of vascular dementia. The Alzheimer's Society, UK. Available from http://www.alzheimers. org.uk/downloads/report_to_summarise_research_priorities_to_ tackle_vascular_dementia.pdf[Accessed 14/3/2008]
   Google Scholar
• Roman GC, Tatemichi TK, Erkinjuntti T. et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43:250-607Roman GC, Tatemichi TK, Erkinjuntti T. et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43:250-60
   Google Scholar
• van der Flier WM, Barkhof F, Scheltens P. Shifting paradigms in dementia: toward stratification of diagnosis and treatment using MRI. Ann N Y Acad Sci 2007;1097:215-248van der Flier WM, Barkhof F, Scheltens P. Shifting paradigms in dementia: toward stratification of diagnosis and treatment using MRI. Ann N Y Acad Sci 2007;1097:215-24
   PubMed Web of Science ®Google Scholar
• Bullock R. Cholinesterase inhibitors and vascular dementia: another string to their bow? CNS Drugs 2004;18:79-929Bullock R. Cholinesterase inhibitors and vascular dementia: another string to their bow? CNS Drugs 2004;18:79-92
   PubMed Web of Science ®Google Scholar
• Kalaria RN, Kenny RA, Ballard CG. et al. Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci 2004;226:75-8010Kalaria RN, Kenny RA, Ballard CG. et al. Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci 2004;226:75-80
   PubMed Web of Science ®Google Scholar
• Bartus RT, Dean RL 3rd, Beer B. et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408-1411Bartus RT, Dean RL 3rd, Beer B. et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408-14
   PubMed Web of Science ®Google Scholar
• Gallagher M, Colombo PJ. Ageing: the cholinergic hypothesis of cognitive decline. Curr Opin Neurobiol 1995;5:161-812Gallagher M, Colombo PJ. Ageing: the cholinergic hypothesis of cognitive decline. Curr Opin Neurobiol 1995;5:161-8
   PubMed Web of Science ®Google Scholar
• Kasa P, Rakonczay Z, Gulya K. The cholinergic system in Alzheimer's disease. Prog Neurobiol 1997;52:511-3513Kasa P, Rakonczay Z, Gulya K. The cholinergic system in Alzheimer's disease. Prog Neurobiol 1997;52:511-35
   PubMed Web of Science ®Google Scholar
• Gottfries CG, Blennow K, Karlsson I. et al. The neurochemistry of vascular dementia. Dementia 1994;5:163-714Gottfries CG, Blennow K, Karlsson I. et al. The neurochemistry of vascular dementia. Dementia 1994;5:163-7
   PubMedGoogle Scholar
• Wallin A, Alafuzoff I, Carlsson A. et al. Neurotransmitter deficits in a non-multi-infarct category of vascular dementia. Acta Neurol Scand 1989;79:397-40615Wallin A, Alafuzoff I, Carlsson A. et al. Neurotransmitter deficits in a non-multi-infarct category of vascular dementia. Acta Neurol Scand 1989;79:397-406
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Kimura M. et al. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 1996;103:1211-2016Tohgi H, Abe T, Kimura M. et al. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 1996;103:1211-20
   PubMed Web of Science ®Google Scholar
• Perry E, Ziabreva I, Perry R. et al. Absence of cholinergic deficits in ‘pure’ vascular dementia. Neurology 2005;64:132-317Perry E, Ziabreva I, Perry R. et al. Absence of cholinergic deficits in ‘pure’ vascular dementia. Neurology 2005;64:132-3
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T, Kurz A, Gauthier S. et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-9018Erkinjuntti T, Kurz A, Gauthier S. et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-90
   PubMed Web of Science ®Google Scholar
• Wilkinson D, Doody R, Helme R. et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003;61:479-8619Wilkinson D, Doody R, Helme R. et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003;61:479-86
   PubMed Web of Science ®Google Scholar
• Black S, Roman GC, Geldmacher DS. et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323-3020Black S, Roman GC, Geldmacher DS. et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323-30
   PubMed Web of Science ®Google Scholar
• Auchus AP, Brashear HR, Salloway S. et al. Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007; 69:448-5821Auchus AP, Brashear HR, Salloway S. et al. Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007; 69:448-58
   PubMed Web of Science ®Google Scholar
• Aguilar M, Roman G, Black S. Efficacy and safety of donepezil in vascular dementia: results from the largest double-blind trial in vascular dementia. Proceedings of the 10th International Conference on Alzheimer's Disease and Related Disorders 15–20 July 2006, Madrid, Spain. P4-43922Aguilar M, Roman G, Black S. Efficacy and safety of donepezil in vascular dementia: results from the largest double-blind trial in vascular dementia. Proceedings of the 10th International Conference on Alzheimer's Disease and Related Disorders 15–20 July 2006, Madrid, Spain. P4-439
   Google Scholar
• Mesulam M, Guillozet A, Shaw P. et al. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:88-9323Mesulam M, Guillozet A, Shaw P. et al. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:88-93
   PubMed Web of Science ®Google Scholar
• Hansen LA, DeTeresa R, Davies P. et al. Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease. Neurology 1988;38:48-5424Hansen LA, DeTeresa R, Davies P. et al. Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease. Neurology 1988;38:48-54
   PubMed Web of Science ®Google Scholar
• Diagnostic criteria from DSM-IV. American Psychiatric Association, 199425Diagnostic criteria from DSM-IV. American Psychiatric Association, 1994
   Google Scholar
• van Straaten EC, Scheltens P, Knol DL. et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke 2003;34:1907-1226van Straaten EC, Scheltens P, Knol DL. et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke 2003;34:1907-12
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T, Inzitari D, Pantoni L. et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000;59:23-3027Erkinjuntti T, Inzitari D, Pantoni L. et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000;59:23-30
   PubMedGoogle Scholar
• Scheltens P, Leys D, Barkhof F. et al. Atrophy of medial temporal lobes on MRI in ‘probable’ Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967-7228Scheltens P, Leys D, Barkhof F. et al. Atrophy of medial temporal lobes on MRI in ‘probable’ Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967-72
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-9829Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98
   Google Scholar
• Ferris SH. Cognitive outcome measures. Alzheimer Dis Assoc Disord 1999;13(Suppl 3):S140-230Ferris SH. Cognitive outcome measures. Alzheimer Dis Assoc Disord 1999;13(Suppl 3):S140-2
   PubMedGoogle Scholar
• Schneider LS, Olin JT, Doody RS. et al. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. The Alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S22-3231Schneider LS, Olin JT, Doody RS. et al. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. The Alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S22-32
   PubMed Web of Science ®Google Scholar
• Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-6432Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64
   PubMed Web of Science ®Google Scholar
• Galasko D, Bennett D, Sano M. et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S33-933Galasko D, Bennett D, Sano M. et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S33-9
   PubMedGoogle Scholar
• Cummings JL, Mega M, Gray K. et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-1434Cummings JL, Mega M, Gray K. et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14
   PubMed Web of Science ®Google Scholar
• Reisberg B, Ferris SH, de Leon MJ. et al. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-935Reisberg B, Ferris SH, de Leon MJ. et al. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9
   PubMed Web of Science ®Google Scholar
• Van Gool WA, Eikelenboom P. The two faces of Alzheimer's disease. J Neurol 2000;247:500-536Van Gool WA, Eikelenboom P. The two faces of Alzheimer's disease. J Neurol 2000;247:500-5
   PubMed Web of Science ®Google Scholar
• Pasquier F, Hamon M, Lebert F. et al. Medial temporal lobe atrophy in memory disorders. J Neurol 1997;244:175-8137Pasquier F, Hamon M, Lebert F. et al. Medial temporal lobe atrophy in memory disorders. J Neurol 1997;244:175-81
   PubMed Web of Science ®Google Scholar
• Kumar V, Anand R, Messina J. et al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000;7:159-6938Kumar V, Anand R, Messina J. et al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000;7:159-69
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T, Skoog I, Lane R. et al. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. Int J Clin Pract 2002;56:791-639Erkinjuntti T, Skoog I, Lane R. et al. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. Int J Clin Pract 2002;56:791-6
   PubMed Web of Science ®Google Scholar
• Rösler M, Anand R, Cicin-Sain A. et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-840Rösler M, Anand R, Cicin-Sain A. et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-8
   PubMed Web of Science ®Google Scholar
• Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-6541Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65
   Google Scholar
• Winblad B, Cummings J, Andreasen N. et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-6742Winblad B, Cummings J, Andreasen N. et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A. et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351:2509-1843Emre M, Aarsland D, Albanese A. et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351:2509-18
   PubMed Web of Science ®Google Scholar
• Feldman HH, Ferris S, Winblad B. et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007;6:501-1244Feldman HH, Ferris S, Winblad B. et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007;6:501-12
   PubMed Web of Science ®Google Scholar
• Ballard C, Lane R, Barone P. et al. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. Int J Clin Pract 2006;60:639-4545Ballard C, Lane R, Barone P. et al. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. Int J Clin Pract 2006;60:639-45
   PubMed Web of Science ®Google Scholar
• Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007;6:782-9246Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007;6:782-92
   PubMed Web of Science ®Google Scholar
• Eisai reports results from latest donepezil study in vascular dementia (news release, March 16, 2006). Eisai Co., Ltd. Available from http://www.eisai.co.jp/enews/enews200609. html [Accessed 17/7/2007]47Eisai reports results from latest donepezil study in vascular dementia (news release, March 16, 2006). Eisai Co., Ltd. Available from http://www.eisai.co.jp/enews/enews200609. html [Accessed 17/7/2007]
   Google Scholar
• Bordier P, Lanusse S, Garrigue S. et al. Causes of syncope in patients with Alzheimer's disease treated with donepezil. Drugs Aging 2005;22:687-9448Bordier P, Lanusse S, Garrigue S. et al. Causes of syncope in patients with Alzheimer's disease treated with donepezil. Drugs Aging 2005;22:687-94
   PubMed Web of Science ®Google Scholar
• Singer W, Opfer-Gehrking TL, McPhee BR. et al. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry 2003;74:1294-849Singer W, Opfer-Gehrking TL, McPhee BR. et al. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry 2003;74:1294-8
   PubMed Web of Science ®Google Scholar
• Burn D, Emre M, McKeith I. et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21: 1899-90750Burn D, Emre M, McKeith I. et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21: 1899-907
   PubMed Web of Science ®Google Scholar
• Birkhofer A, Schmidt G, Förstl H. Heart and brain – the influence of psychiatric disorders and their therapy on the heart rate variability [in German]. Fortschr Neurol Psychiatr 2005; 73:192-20551Birkhofer A, Schmidt G, Förstl H. Heart and brain – the influence of psychiatric disorders and their therapy on the heart rate variability [in German]. Fortschr Neurol Psychiatr 2005; 73:192-205
   PubMed Web of Science ®Google Scholar
• Allan L, McKeith I, Ballard C. et al. The prevalence of autonomic symptoms in dementia and their association with physical activity, activities of daily living and quality of life. Dement Geriatr Cogn Disord 2006;22:230-752Allan L, McKeith I, Ballard C. et al. The prevalence of autonomic symptoms in dementia and their association with physical activity, activities of daily living and quality of life. Dement Geriatr Cogn Disord 2006;22:230-7
   PubMed Web of Science ®Google Scholar
• Miller JW, Green R, Mungas DM. et al. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology 2002; 58: 1471-553Miller JW, Green R, Mungas DM. et al. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology 2002; 58: 1471-5
   PubMed Web of Science ®Google Scholar
• Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007;6:782-9254Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007;6:782-92
   PubMed Web of Science ®Google Scholar
• Skoog I, Nilsson L, Palmertz B. et al. A population-based study of dementia in 85-year-olds. N Engl J Med 1993;328:153-855Skoog I, Nilsson L, Palmertz B. et al. A population-based study of dementia in 85-year-olds. N Engl J Med 1993;328:153-8
   PubMed Web of Science ®Google Scholar
• Mungas D, Reed BR, Ellis WG. et al. The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch Neurol 2001;58:1243-756Mungas D, Reed BR, Ellis WG. et al. The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch Neurol 2001;58:1243-7
   PubMed Web of Science ®Google Scholar
• Black SE. Therapeutic issues in vascular dementia: studies, designs and approaches. Can J Neurol Sci 2007;34(Suppl 1): S125-3057Black SE. Therapeutic issues in vascular dementia: studies, designs and approaches. Can J Neurol Sci 2007;34(Suppl 1): S125-30
   PubMed Web of Science ®Google Scholar
• Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 2000;21:321-3058Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 2000;21:321-30
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C. et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-4659Dubois B, Feldman HH, Jacova C. et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46
   PubMed Web of Science ®Google Scholar